<SEC-DOCUMENT>0001628280-24-045031.txt : 20241104
<SEC-HEADER>0001628280-24-045031.hdr.sgml : 20241104
<ACCEPTANCE-DATETIME>20241104164251
ACCESSION NUMBER:		0001628280-24-045031
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20241104
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241104
DATE AS OF CHANGE:		20241104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adverum Biotechnologies, Inc.
		CENTRAL INDEX KEY:			0001501756
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				205258327
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36579
		FILM NUMBER:		241424293

	BUSINESS ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		(650) 649-1004

	MAIL ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avalanche Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20100921
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>advm-20241104.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:11bdd552-4341-477c-9403-f6a20e9776a6,g:dd6625fe-7f6e-4d0e-a102-95da388bb827,d:d5af8a325b6749bcb87a7273f0031a97-->
<html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>advm-20241104</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-21">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001501756</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="advm-20241104.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-04</xbrli:startDate><xbrli:endDate>2024-11-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id5af8a325b6749bcb87a7273f0031a97_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.438%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.438%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November 4, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.586%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Adverum Biotechnologies, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.438%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.296%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36579</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">20-5258327</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">100 Cardinal Way</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Redwood City</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">CA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94063</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">656-9323</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.438%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a&#8211;12 under the Exchange Act (17 CFR 240.14a&#8211;12)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d&#8211;2(b) under the Exchange Act (17 CFR 240.14d&#8211;2(b))</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e&#8211;4(c) under the Exchange Act (17 CFR 240.13e&#8211;4(c))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">ADVM</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id5af8a325b6749bcb87a7273f0031a97_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Results of Operations and Financial Condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">On November 4, 2024, Adverum Biotechnologies, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2024, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The information in this report, including the exhibit hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Adverum Biotechnologies, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div id="id5af8a325b6749bcb87a7273f0031a97_10"></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit991_110424pressrele.htm">Press Release dated November 4, 2024, announcing Adverum Biotechnologies, Inc. financial results for the quarter ended September 30, 2024, and providing a corporate update.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The cover page of this report has been formatted in Inline XBRL.</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id5af8a325b6749bcb87a7273f0031a97_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.397%"><tr><td style="width:1.0%"/><td style="width:47.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.178%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Adverum Biotechnologies, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-23">November&#160;4, 2024</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">/s/ Laurent Fischer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Laurent Fischer, M.D. <br/>President and Chief Executive Officer</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991_110424pressrele.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i58b74c195919468bb1154c205ee41ae9_1"></div><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><img alt="logoa.jpg" src="logoa.jpg" style="height:58px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">-  52-week LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">- Appointed Jason Mitchell as chief commercial officer</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">-  On-track to initiate pivotal program in 1H 2025</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">- $153.2 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025</font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">REDWOOD CITY, Calif., November 4, 2024 -- </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Adverum Biotechnologies, Inc. (Nasdaq&#58; ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter of 2024 and provided updates to anticipated milestones.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;We remain laser focused on initiating our Phase 3 program and progressing Ixo-vec toward approval and commercialization,&#8221; stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies. &#8220;Over the past year we&#8217;ve presented LUNA clinical data supporting what I believe to be the best-in-class product candidate for wet AMD patients. These data echo, and even improve upon,  Ixo-vec&#8217;s robust and durable efficacy and favorable long-term safety profile which have been demonstrated out to 3 years.  Later this quarter we look forward to presenting the LUNA 52-week data alongside the 4-year OPTIC data. We are closing in on our goal to bring a potentially transformational gene therapy to wet AMD patients, who suffer from a life-long disease that, even with the best available agents, requires frequent injections into the eye.&#8221; </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Corporate Highlights</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">Appointed Jason Mitchell as Chief Commercial Officer </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">In October 2024, we announced the appointment of Jason L. Mitchell as chief commercial officer. Mr. Mitchell brings to Adverum over 20 years of commercial experience, including most recently in retinal disease, where he oversaw the successful launch of SYFOVRE&#174;, the first treatment approved for geographic atrophy (GA). In his new role, Mr. Mitchell will be responsible for setting the launch strategy and building the commercial infrastructure for Ixo-vec, Adverum&#8217;s one-time intravitreal injection for the treatment of neovascular or wet AMD.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Upcoming Anticipated Milestones</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">4Q 2024&#58; LUNA 52-week data update, including all-available safety follow-up </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">4Q 2024&#58; OPTIC 4-year clinical data update</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">4Q 2024&#58; Phase 3 pivotal trial design update</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">H1 2025&#58; Planned initiation of Phase 3 trial</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Results for the Three Months Ended September 30, 2024</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Cash, cash equivalents and short-term investments</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> were $153.2 million as of September&#160;30, 2024, compared to $96.5 million as of December 31, 2023. Adverum expects its cash, cash equivalents and short-term investments to fund operations into late 2025.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Research and development expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> were $20.4 million for the three months ended September&#160;30, 2024, compared to $20.7 million for the same period in 2023. Research and development expenses decreased due to lower facilities related expenses partially offset by higher spending on Ixo-vec clinical development and higher compensation expenses. Stock-based compensation expense included in research and development expenses was $1.1&#160;million for the third quarter of 2024.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">General and administrative expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> were $9.8 million for the three months ended September&#160;30, 2024, compared to $13.8 million for the same period in 2023. General and administrative expenses decreased due to lower facilities related expenses, lower depreciation expense, and lower compensation expenses due lower stock-based compensation expense. Stock-based compensation expense included in general and administrative expenses was $1.9&#160;million for the third quarter of 2024.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Net loss</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> was $27.1 million, or $1.30 per basic and diluted share, for the three months ended September&#160;30, 2024, compared to $32.9 million, or $3.26 per basic and diluted share for the same period in 2023. </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Wet Age-Related Macular Degeneration</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Wet AMD, also known as neovascular AMD or nAMD, is a VEGF-driven advanced form of age-related macular degeneration (AMD) associated with the build-up of fluid in the macula and the retina. Wet AMD is a leading cause of blindness in people over 65 years of age, with approximately 20 million individuals worldwide living with this condition. New cases of wet AMD are expected to grow significantly worldwide as populations age. AMD is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately 10% of those cases. Additionally, wet AMD is a bilateral disease, and incidence of nAMD in the second eye is up to 42% in the first two to three years. The current standard of care requires frequent life-long bolus injections of anti-VEGF in the eye.  Intravitreal (IVT) gene therapy has the promise to preserve vision and reduce most or all injections for the life of the patient by delivering stable therapeutic levels of anti-VEGF to control fluid associated with the disease.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Ixo-vec in Wet AMD</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adverum is developing ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), its clinical-stage gene therapy product candidate, for the treatment of wet AMD. Ixo-vec utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. Unlike other ophthalmic gene therapies that require surgery to administer the gene therapy under the retina (sub-retinal approach), Ixo-vec is designed to be administered as a one-time IVT injection in the physician&#8217;s office, deliver long-term efficacy, reduce the burden of frequent anti-VEGF injections into the eye, optimize patient compliance and improve vision outcomes for patients with wet AMD. Ixo-vec is currently being evaluated for the treatment of neovascular or wet AMD in the ongoing LUNA Phase 2 clinical trial (</font><font style="background-color:#ffffff;color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">NCT05536973</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) and the OPTIC Phase 1 extension study (</font><font style="background-color:#ffffff;color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">NCT04645212</font><font style="background-color:#ffffff;color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In recognition of the need for new treatment options for wet AMD, FDA has granted Fast Track and RMAT designations for Ixo-vec for the treatment of wet AMD. Ixo-vec has also received PRIME designation from the European Medicines Agency and the Innovation Passport from the United Kingdom&#8217;s Medicines and Healthcare products Regulatory Agency for the treatment of wet AMD.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Adverum Biotechnologies</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adverum Biotechnologies (NASDAQ&#58; ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians&#8217; offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.adverum.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-looking Statements</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Statements contained in this press release regarding events or results that may occur in the future are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements regarding the anticipated timing of clinical data and trial design update for the Phase 3 LUNA trial and initiation of a Phase 3 trial, the Company&#8217;s cash sufficiency and runway, expectations concerning the decisions of regulatory bodies, the therapeutic and commercial potential of Ixo-vec, and the favorable safety profile and potential best-in-class product profile of Ixo-vec. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including risks inherent to, without limitation&#58; Adverum&#8217;s novel technology, which makes it difficult to predict the timing of commencement and completion of clinical trials&#59; regulatory uncertainties&#59; enrollment uncertainties&#59; the results of early clinical trials not always being predictive of future clinical trials and results&#59; the potential for future complications or side effects in connection with use of Ixo-vec&#59; and risks associated with market conditions. Additional risks and uncertainties facing Adverum are set forth under the caption &#8220;Risk Factors&#8221; and elsewhere in Adverum&#8217;s Securities and Exchange Commission (SEC) filings and reports, including Adverum&#8217;s most recent Annual Report on Form 10-K filed with the SEC, as updated by any subsequent reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Corporate, Investor and Media Inquiries</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adverum Biotechnologies, Inc. </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">E&#58; </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ir&#64;adverum.com</font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.235%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Adverum Biotechnologies, Inc.</font></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Selected Consolidated Balance Sheet Data</font></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(In thousands)</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">September 30,</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">December 31,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2023</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(1)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents, and marketable securities</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">153,241&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">96,526&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total assets</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">234,375&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">173,010&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total current liabilities</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">27,657&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">24,914&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total stockholders' equity</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">144,116&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">83,469&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:107%">(1) </font><font style="color:#636363;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:107%">Derived from Adverum&#8217;s annual audited consolidated financial statements.</font></div></td></tr></table></div><div><font><br></font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Adverum Biotechnologies, Inc.</font></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Condensed Consolidated Statements of Operations</font></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(In thousands except per share data)</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Three months ended September 30,</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Nine months ended September 30,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2023</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Unaudited)</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">License revenue</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3,600&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating expenses&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20,439&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20,740&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">52,946&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">62,398&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">General and administrative</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9,782&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">13,789&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">24,996&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">39,035&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total operating expenses</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">30,221&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">34,529&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">77,942&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">101,433&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating loss</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(29,221)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(34,529)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(76,942)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(97,833)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other income, net</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2,087&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,661&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6,545&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4,437&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net loss before income taxes</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(27,134)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(32,868)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(70,397)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(93,396)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Income tax provision</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(17)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(55)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net loss</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(27,134)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(32,885)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(70,397)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(93,451)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net loss per share &#8212; basic and diluted</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1.30)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(3.26)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(3.63)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(9.28)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Weighted-average common shares outstanding - basic and diluted</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20,876</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10,100</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">19,408</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10,069</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>advm-20241104.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:11bdd552-4341-477c-9403-f6a20e9776a6,g:dd6625fe-7f6e-4d0e-a102-95da388bb827-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:advm="http://www.adverum.com/20241104" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.adverum.com/20241104">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20241104_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20241104_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.adverum.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>advm-20241104_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:11bdd552-4341-477c-9403-f6a20e9776a6,g:dd6625fe-7f6e-4d0e-a102-95da388bb827-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_74689fb3-3b5c-450f-8b67-b0ef39ea83f9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7e6594d5-6c40-4d7c-9a43-ada8a34cb804_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0ece3060-d319-46cf-9e90-a59dc769d13b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b448a802-0065-4faf-b1cd-ea111e37db6a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_44e75efe-00c1-4a9d-9591-5871c37ac45f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_037bd8ee-6939-4648-9929-afe8da0abcd2_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3466261c-b36d-4008-97d2-9d6a9b599ddc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_af0b9cee-3f67-4be1-9e4e-a075643cb160_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_7262b868-4e9c-4779-aded-dc78622ab79f_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d490ced2-cd66-4a85-bc33-40131e799857_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_0a990b0b-d0f6-4cbc-aff1-a50caf849df5_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8984b6e0-9ffe-453c-b946-daaf0aae8cf5_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_dc928479-4e7f-462c-899e-7db525af2bef_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6f028f89-b20f-4720-9b61-a3051f4ae0fe_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8a099eb7-675b-4af7-9db1-ea0bd403e4cf_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7846e7ed-5eed-47a1-ad0f-425bc07902c6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_c6001e3c-154e-447e-80d0-0b4c30525f2b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_226b2f55-6d97-43af-b817-3ca68a6ab732_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_7825c4b3-8bd8-422e-8beb-d3992bd97c0a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_897de9cb-4a02-48fd-b956-ba0722f3f30d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9f67ce95-5340-41f3-8b7c-84d3c331e805_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3407b4cd-8803-4f74-977d-7183e571d107_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>advm-20241104_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:11bdd552-4341-477c-9403-f6a20e9776a6,g:dd6625fe-7f6e-4d0e-a102-95da388bb827-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adverum.com/role/Cover" xlink:type="simple" xlink:href="advm-20241104.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8c4b81ca-5d11-4edc-b5e7-c0654c1a4d2b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_DocumentType_8c4b81ca-5d11-4edc-b5e7-c0654c1a4d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_90d45bfd-35f7-484a-8cd7-a22ba12bdb0d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_DocumentPeriodEndDate_90d45bfd-35f7-484a-8cd7-a22ba12bdb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ec1595c7-9c4c-4f2e-8da4-6fdc4166391e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_EntityRegistrantName_ec1595c7-9c4c-4f2e-8da4-6fdc4166391e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8eb517f7-397b-4cde-92b8-8e1715a44368" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8eb517f7-397b-4cde-92b8-8e1715a44368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9e98af15-4fdf-4d34-92fe-7b002833e890" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_EntityFileNumber_9e98af15-4fdf-4d34-92fe-7b002833e890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f23031b4-ef29-4ad5-8519-e2ac3a1ae8a9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_EntityTaxIdentificationNumber_f23031b4-ef29-4ad5-8519-e2ac3a1ae8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e3f0b6d5-f46c-4f4d-9e78-f29930a1e014" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_EntityAddressAddressLine1_e3f0b6d5-f46c-4f4d-9e78-f29930a1e014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a77edca1-ab40-449f-970d-9837ea082100" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_EntityAddressCityOrTown_a77edca1-ab40-449f-970d-9837ea082100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_537fbb26-2784-49e9-bf4f-64b486fe5a79" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_EntityAddressStateOrProvince_537fbb26-2784-49e9-bf4f-64b486fe5a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1536cd59-d262-454b-9b96-70ca67ecb234" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_EntityAddressPostalZipCode_1536cd59-d262-454b-9b96-70ca67ecb234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0aa0c732-aead-4e08-b5a5-4c64bf52a3f6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_CityAreaCode_0aa0c732-aead-4e08-b5a5-4c64bf52a3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2f2bb8ab-a9e3-494f-b95e-caf07aa51709" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_LocalPhoneNumber_2f2bb8ab-a9e3-494f-b95e-caf07aa51709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_55fefe8f-9306-48c3-abb3-806548756dbf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_WrittenCommunications_55fefe8f-9306-48c3-abb3-806548756dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_7209ad89-92fd-494e-af10-58a30a3fd56f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_SolicitingMaterial_7209ad89-92fd-494e-af10-58a30a3fd56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_b8d52495-c1d3-46fc-b152-01cd2e4442c5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_PreCommencementTenderOffer_b8d52495-c1d3-46fc-b152-01cd2e4442c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_d2f2b23d-03c9-41cf-896d-1d015f0def26" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_d2f2b23d-03c9-41cf-896d-1d015f0def26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b97a9c23-8af5-412d-9d22-d9af54af897f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_Security12bTitle_b97a9c23-8af5-412d-9d22-d9af54af897f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_16094f43-fdef-4e86-afdd-9f3a35a2b868" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_TradingSymbol_16094f43-fdef-4e86-afdd-9f3a35a2b868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e2499f9c-3af1-4f1b-bdef-225ea1df843e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_EntityCentralIndexKey_e2499f9c-3af1-4f1b-bdef-225ea1df843e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2898b6b9-2f85-4ab4-bea4-4398c82041cc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_EntityEmergingGrowthCompany_2898b6b9-2f85-4ab4-bea4-4398c82041cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_24bd7f06-0fe6-4ddf-9e01-398d222a648e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_AmendmentFlag_24bd7f06-0fe6-4ddf-9e01-398d222a648e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0ec04251-5388-4fad-91d7-2fbd135c3981" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66a633b-a32b-4fe8-b2b3-729ecf3124a7" xlink:to="loc_dei_SecurityExchangeName_0ec04251-5388-4fad-91d7-2fbd135c3981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>logoa.jpg
<TEXT>
begin 644 logoa.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "? ?$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **3-+0 4444 %%%)F@!:*3-&: %HHHH ***3- "T4E+0 4444 %%%)0 M%)
MFEH **3-+0 4444 %%)FC(H 6BDI: "BBDR* %HHHH **2EH ***2@!:***
M"BBDH 6BBB@ HHHH ***2@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M.)^''[27A7XF^*)]#TQKB.Z4,T33( LRKU*UZTO2OSM_9%_Y+7HO_7"7_P!
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M\;8S@CZ5\1_M2?$;_A/OB==0P2[]-TH&T@QT+ _.P^IX_ 5[5^P?QX7\3?\
M7['_ .@&NMT5&GS'QF&SN>)S1X6-N17_  /J44ZFX/>G5R'V@M%%% !1110
M4444 %%%% !1110 4444 %(W2BD9AB@#RW]HKXD+\-_AM?W43A=0NE^S6JYP
M=[<9'T'-?.G[&OPU;Q)XIO/%6H1F2VL<I"SCAYFZG\ :Q/VJ/'D_Q(^*<7A[
M3"T]KITGV2)$Y#W#'#'\#Q^!K["^$'@&'X;^ =+T:-1YT<8>=A_%(1EC^?\
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MIJM.A3;W9V?[(/Q";P;\1)= O6,-IJF8=K'A)U/']17WAVK\]?VDO!4_PO\
MBX^I6"M!;7KB_M77@+)G+ ?CS^-?;/PF\<0_$/P'I6MQ,&>:("8?W9!PP^N?
MYU-:*=IHZ.'ZTJ,JF7U=X/3T.RZUYM\?_B(GPW^&NJ:@CA;V9?L]JN>3(PQG
M\!S^%>D# 6OA3]LCXBMXI\=Q>'K1]]II(VLJG(>9L9_+@5E2AS2/8SK&?4\)
M*4?B>B^9X='H=Y?:'?:XP)M8+A('D;JTCY.!^ .:^M_V#L_\(SXF_P"OR/\
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MQ9N;/<?X3]]?P//XU]:"N*K>,K,^[RBM2Q&$A.G&W1^IB>.O^1,US_KRF_\
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M'B:68T^CLS]$[JYCL[>6>5@D<:EV)Z  9S7YO^/M6O?CA\:IEM"TGV^[%I;
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I*6B@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
,* "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45898088739696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 04, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  04,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adverum Biotechnologies, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-5258327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Cardinal Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">656-9323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADVM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MD9N!XSOO#Y[Y<F7L W?8S^B2S9CY*YLJ:+FE2LQ3)C27@BBV&#@C_^8VZ-B
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 6(5D6:K$(A8S 0  (@(
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " !8A61999!YDAD!  #/ P  $P
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 6(5D69E<G",0!@
MG"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " !8A619"VZ+(C@$  !K$   &               @($-"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 6(5D69^@&_"Q @
MX@P   T              ( !>PP  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" !8A619EXJ[',     3 @  "P              @ %7#P  7W)E;',O+G)E
M;'-02P$"% ,4    " !8A619JL0B%C,!   B @  #P              @ %
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 6(5D620>FZ*M    ^ $
M !H              ( !H!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ 6(5D6660>9(9 0  SP,  !,              ( !A1(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  SQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="advm-20241104.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="advm-20241104.htm">advm-20241104.htm</File>
    <File>advm-20241104.xsd</File>
    <File>advm-20241104_lab.xml</File>
    <File>advm-20241104_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "advm-20241104.htm": {
   "nsprefix": "advm",
   "nsuri": "http://www.adverum.com/20241104",
   "dts": {
    "inline": {
     "local": [
      "advm-20241104.htm"
     ]
    },
    "schema": {
     "local": [
      "advm-20241104.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "advm-20241104_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "advm-20241104_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.adverum.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20241104.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20241104.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-24-045031-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-045031-xbrl.zip
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M#F8T/QZ)Y];K.B/06\>J9+Q86O3"M:X#LT9:'SK$L@T=.A9=SGL-[.A& ?<
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M[B<W0HP]CB<6YGYZNR(]8.\NV*]:WI;&\?M[>6T^9/V)+_4<8TUCG6HC5!E
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M4\-8;%)^W:;=+J2P+)2@!9P:"RCF+>"U,@VC]2Z-%G,(BC'!H*@";N3Z1IK
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MP$?^Q;ZA"L7<(Y>^8GE!F+;W:Y1?#)5_ 7]-DFGPZO\!4$L! A0#%     @
M6(5D6;M-"&L>#P  \UX  !$              ( !     &%D=FTM,C R-#$Q
M,#0N:'1M4$L! A0#%     @ 6(5D67B;4>U> @  ]@8  !$
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?<W)E;&4N:'1M4$L%!@     %  4 4 $  %X[      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>advm-20241104_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="advm-20241104.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2024-11-04</startDate>
            <endDate>2024-11-04</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001501756</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-11-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Adverum Biotechnologies, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36579</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">20-5258327</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">100 Cardinal Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94063</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">656-9323</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">ADVM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-23">2024-11-04</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
